Obsidian and Galera Therapeutics Announce $350 Million Merger to Advance Next-Generation TIL Cell Therapy
核心洞察
Obsidian Therapeutics (搜索) and Galera Therapeutics (搜索) have agreed to merge in an all-stock transaction backed by $350 million in new financing to create a publicly traded cell therapy company.
The combined company will focus on advancing OBX-115, an engineered tumor infiltrating lymphocyte therapy currently in Phase II trials for melanoma (搜索) and Phase I trials for non-small cell lung cancer (搜索).
OBX-115 incorporates regulatable membrane-bound IL15 (搜索) technology that eliminates the need for toxic interleukin-2 and enables outpatient administration with low-dose lymphodepletion.
Obsidian Therapeutics (搜索) and Galera Therapeutics (搜索) have entered into a definitive merger agreement to combine in an all-stock transaction backed by $350 million in new financing, creating a publicly traded cell therapy company focused on advancing next-generation tumor infiltrating lymphocyte (TIL) therapies for solid tumors (搜索).
The transaction will establish a combined entity operating under the name Obsidian Therapeutics (搜索), with plans to trade on Nasdaq under the ticker symbol "OBX." The merger is expected to close by the third quarter of 2026, subject to stockholder approvals and customary conditions. Madan Jagasia, Obsidian's current CEO, will lead the combined company.
$350 Million Financing Supports Clinical Development
Supporting the merger is an oversubscribed $350 million private placement from a syndicate of new and existing investors including Balyasny Asset Management (搜索), Redmile (搜索), RA Capital Management (搜索), Novo Holdings (搜索), Wellington Management (搜索), and others. The combined company's cash position is expected to fund operations into the second half of 2028 and through key clinical milestones for Obsidian's lead asset OBX-115.
At closing, pre-merger Obsidian stockholders are expected to own approximately 53.2% of the combined company, private placement investors approximately 45%, and pre-merger Galera stockholders approximately 1.8%.
OBX-115: Addressing TIL Therapy Limitations
OBX-115 is Obsidian's lead engineered TIL cell therapy, currently in a Phase II trial for advanced melanoma (搜索) and a Phase I trial for non-small cell lung cancer (搜索). Built on Obsidian's cytoDRIVE platform, the therapy is designed to address key limitations of existing TIL therapies.
Conventional TIL therapies require high-dose interleukin-2, a toxic cytokine administered to help transplanted cells survive, and inpatient lymphodepletion before infusion. OBX-115 incorporates regulatable membrane-bound IL15 (搜索), which drives TIL persistence and eliminates the need for IL2, enabling outpatient administration with low-dose lymphodepletion.
The therapy can also be manufactured from tumor tissue obtained through a minimally invasive core needle biopsy rather than a surgical procedure, lowering the procedural burden on patients. The FDA has granted OBX-115 both Fast Track and Regenerative Medicine Advanced Therapy designations for unresectable or metastatic melanoma (搜索) resistant to immune checkpoint inhibitors.
"At Obsidian, we are striving to deliver a best-in-class TIL cell therapy developed using our proprietary protein-regulation technology," said Madan Jagasia, CEO of Obsidian. "We believe OBX-115 offers an opportunity to provide patients with an improved TIL product and patient experience. This transaction and the support from leading life sciences investors will allow us to advance our development plans for OBX-115 in melanoma (搜索) and NSCLC (搜索)."
Clinical Milestones and Strategic Value
Key upcoming milestones include Phase I data from the NSCLC (搜索) trial expected in the first half of 2027 and topline data from the melanoma (搜索) registration-enabling trial by year-end 2027. These near-term catalysts are expected to provide value-creating opportunities for the combined company.
Galera contributes its Nasdaq listing and cash to the combination, providing the vehicle for Obsidian to access public markets. Galera stockholders will retain a contingent value right entitling them to 95% of future milestone proceeds for up to ten years from Galera's October 2025 asset purchase agreement with Biossil.ai (搜索) for its dismutase mimetics program.
"We believe this transaction with Obsidian is the best path forward for Galera and look forward to the combined company's success," said J. Mel Sorensen, CEO of Galera. "Obsidian's pipeline of novel engineered TIL cell therapies and its promising lead product candidate, OBX-115, offer near-term, value creating milestones for Galera stockholders."
The merger represents a strategic combination that positions the combined entity to advance innovative TIL cell therapy technology while providing sufficient capital runway to reach key clinical inflection points in both melanoma (搜索) and lung cancer (搜索) indications.